Zacks Investment Research upgraded shares of Gemphire Therapeutics Inc. (NASDAQ:GEMP) from a sell rating to a hold rating in a research note published on Monday, October 16th. They currently have $11.00 price objective on the stock.
According to Zacks, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. “
A number of other brokerages have also recently issued reports on GEMP. Jefferies Group LLC raised their target price on shares of Gemphire Therapeutics to $32.00 and gave the stock a buy rating in a report on Tuesday, August 1st. Canaccord Genuity set a $31.00 target price on shares of Gemphire Therapeutics and gave the stock a buy rating in a report on Wednesday, July 26th. Finally, HC Wainwright began coverage on shares of Gemphire Therapeutics in a report on Thursday, August 31st. They issued a buy rating and a $21.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $23.33.
Shares of Gemphire Therapeutics (NASDAQ:GEMP) opened at 9.295 on Monday. The stock’s market capitalization is $98.77 million. The firm has a 50 day moving average price of $9.65 and a 200 day moving average price of $9.65. Gemphire Therapeutics has a one year low of $7.25 and a one year high of $11.37.
Gemphire Therapeutics (NASDAQ:GEMP) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.28). Analysts predict that Gemphire Therapeutics will post ($2.98) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Gemphire Therapeutics Inc. (NASDAQ:GEMP) Stock Rating Upgraded by Zacks Investment Research” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/10/27/zacks-investment-research-upgrades-gemphire-therapeutics-inc-gemp-to-hold.html.
Several large investors have recently made changes to their positions in the business. Northpointe Capital LLC increased its stake in shares of Gemphire Therapeutics by 91.8% in the third quarter. Northpointe Capital LLC now owns 520,292 shares of the company’s stock valued at $4,943,000 after purchasing an additional 249,077 shares during the period. Advisory Services Network LLC acquired a new position in shares of Gemphire Therapeutics during the second quarter valued at approximately $139,000. GM Advisory Group Inc. acquired a new position in shares of Gemphire Therapeutics during the second quarter valued at approximately $457,000. Vanguard Group Inc. increased its stake in shares of Gemphire Therapeutics by 137.6% during the second quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock valued at $399,000 after acquiring an additional 17,892 shares during the period. Finally, Cambridge Investment Research Advisors Inc. increased its stake in shares of Gemphire Therapeutics by 1.7% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 153,064 shares of the company’s stock valued at $1,959,000 after acquiring an additional 2,500 shares during the period. Institutional investors own 29.72% of the company’s stock.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.